* Uniqure presents updated clinical data in patients with
severe Hemophilia B demonstrating up to 9 months of sustained
levels of factor IX activity and therapeutic effect
Source text for Eikon:
Further company coverage:
(Bengaluru Newsroom: +1-646-223-8780)
Read more
No comments:
Post a Comment